Innovation

Driven by Compassion

Home

LATE-BREAKING DATA: AVTX-002 
Moderate to Severe Crohn’s Disease Study Results

Download Presentation

About Us

We are a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in the areas of immunology, immuno-oncology and rare disease.

Our Approach

Our highly targeted clinical-stage therapeutics are founded on a strong scientific and clinical rationale that may enable accelerated clinical development and increased probability of clinical and regulatory success.

Our Pipeline

We are rapidly advancing a rich pipeline with the potential for broad clinical utility across Immunology, Immuno-oncology, and Rare Genetic Diseases.

Differentiating Attributes of Our Programs


  • Novel mechanisms offering potential as first-in-class medications
  • First available therapy and/or substantial improvement over existing therapies for serious diseases
  • Targeted mechanisms of action with the potential for a favorable benefit-risk profile
  • Candidates for accelerated clinical development and regulatory pathways
  • Identified biomarkers and/or published clinical proof of concept increase the probability regulatory approval
  • Associated biomarkers offer the potential for better patient identification and higher response rates
View Pipeline